Silver from London: PatientsForce Named a Global Good Trailblazer 2026
A Silver Medal for Access, at BMA House in London
On 24 September 2026, the Global Good Awards held its annual ceremony at BMA House in London. PatientsForce received Silver in the Global Good Trailblazer of the Year category; the Tzu Chi Foundation took Bronze in Community Partnership of the Year. Two Taiwanese organisations shared a stage judged primarily on sustainability and social impact.
For us the significance is not the trophy. It is that the judging panel recognised the gap we have spent years working inside: the window between a medicine being licensed and that medicine being reimbursed.
The Gap Is a Real Wait
Every health system has to draw a line on what it can afford. Where the line sits is a policy choice, but there will always be patients on the other side of it. After a new medicine clears registration, reimbursement review can take months or years. For patients with chronic conditions that time is a wait. For patients with advanced cancer or a rare disease, that time may be the treatment window itself.
Taiwan has made its commitment explicit — the NT$10 billion Cancer Drug Fund running across 2025 and 2026 is a concrete policy signal. A patient support programme is not a substitute for that. Its job is to make the interval manageable rather than terminal.
2017 to 2025, in Numbers
- NT$10 billion in medicine subsidies delivered
- More than 30,000 patients supported every year
- Programmes run on behalf of 50+ domestic and international pharmaceutical companies
- Coverage spanning 100+ medicines and over 70% of cancer types
Behind those figures is an operating system that links eligibility screening, documentation, subsidy reconciliation, medicine delivery and nursing follow-up into a single flow. Within the applicable regulatory framework, we also collect real-world data on treatment initiation, adherence and outcomes — so a support programme can be measured on whether it actually helped, not only on how much was dispensed.
From the Founders
Sean Chang, Founder and President, noted that Taiwan has shown real commitment to bringing innovative medicines to patients sooner, and that patient support programmes, done well, complement that effort rather than replace it.
Evie Wang, Co-founder and Chief Operating Officer, put it this way: every health system has to draw a line on what it can afford, and that line will always leave some patients waiting. "Our job is to make sure the wait doesn't become the end of the road."
What Comes Next
The award does not change our direction, only its range. We will keep deepening collaboration with hospitals, physicians and pharmaceutical partners in Taiwan, while extending the patient support network into Hong Kong and Southeast Asia. Reimbursement systems and regulatory environments differ across Asia. The gap between approval and access does not.
Sources and Further Reading
This article was written by PatientsForce. Related coverage and the original release:
- United Daily News, "Taiwan's PatientsForce wins Silver in the Global Good Trailblazer category", by Lee Shu-jen, 1 October 2026
- PatientsForce release, "Closing the gap between approval and access: Taiwan's PatientsForce wins Silver at the Global Good Awards 2026" (PR Newswire, 2 October 2026, London and Taipei)
- Global Good Awards 2026 winners list (globalgoodawards.co.uk)